` BMT (Beamtree Holdings Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BMT
vs
S
S&P/ASX 300

Over the past 12 months, BMT has underperformed S&P/ASX 300, delivering a return of -21% compared to the S&P/ASX 300's +5% growth.

Stocks Performance
BMT vs S&P/ASX 300

Loading
BMT
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BMT vs S&P/ASX 300

Loading
BMT
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
BMT vs S&P/ASX 300

Loading
BMT
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Beamtree Holdings Ltd vs Peers

S&P/ASX 300
BMT
VEEV
PME
2413
DOCS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Beamtree Holdings Ltd
Glance View

Market Cap
59.5m AUD
Industry
Health Care

Beamtree Holdings Ltd. is an Australian healthcare technology company. The company is headquartered in Sydney, New South Wales. The company went IPO on 2019-06-06. The firm work with health organizations to capture, manage and leverage human skills. The firm enables healthcare providers to access information, automate wherever possible and make informed decisions. Its products and services include picq, RippleDown Expert, RippleDown Auditor, RISQ, Q Coding platform and codexpert. RippleDown Expert automatically applies clinical solutions to generate patient-centric reports. Its Q Coding platform provides an end-to-end workflow suite for clinical coding, grouping, reporting and auditing. RippleDown Auditor automates real-time reviews of all data in pathology. Codexpert is used in clinical coding classification reference. RISQ improves identification and benchmarking better patient care.

BMT Intrinsic Value
0.441 AUD
Undervaluation 54%
Intrinsic Value
Price
Back to Top